Upgrade to SI Premium - Free Trial

Truist Securities Reiterates Buy Rating on Intellia Therapeutics (NTLA)

June 24, 2024 10:32 AM
Truist Securities analyst Joon Lee reiterated a Buy rating and $120.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles